"Over a 7-day period, the researchers assessed the following actigraphy variables: sleep onset latency, wake after sleep onset, sleep efficiency, total time in bed, total sleep time, number of awakenings, and average time awake during awakenings. Phlebotomy for biomarkers was also performed.
The results of the study showed that the participants had poor sleep quality, impaired physical function, sleep-related impairment, reduced health-related quality of life, and objective signs of insomnia.
The researchers also found that the actigraphy sleep variables were associated with the sympathetic nervous system (norepinephrine), the hypothalamic pituitary adrenal axis (copeptin), and inflammation (C-reactive protein).
Lea Ann Matura, PhD, RN, an associate professor at the University of Pennsylvania’s School of Nursing, was the study’s lead author. Pulmonology Consultant asked her about these findings and how they may aid you in selecting targeted interventions to treat your patients with PAH."
Read more here.